ONCODONA

Oncodona is the most advanced genetic test for early identification of predisposition to inherited cancer.
This test analyzes 21 genes related to breast and ovarian cancer in order to locate mutations that increase the risk of developing these types of cancer.
Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

This test is recommended if:

You’ve been diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. Oncodona can find a mutation in up to 4% of women.
A woman in your family has been diagnosed with breast and ovarian cancer.
You just want to know if you have any risk of developing breast and ovarian cancer.

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
A negative result means that the patient does not have an increased risk. In other words, their risk of suffering one of the types of cancer analysed by the test is the baseline risk of the population.